Familial amyloidosis
Drug research and approvals for familial amyloidosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 73 studies of familial amyloidosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 73
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 73 recruiting on ClinicalTrials.gov ↗
- Liver and Coagulation Disorders in Cardiac Transthyretin AmyloidosisNCT07766135 · Not reported · University of Messina · starts Jan 30, 2026
- Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis -…NCT07752732 · Not reported · University Hospital Tuebingen · starts Jan 14, 2020
- Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisNCT07695701 · Phase 4 · Eidos Therapeutics, a BridgeBio company · starts Jul 28, 2026
- Hungarian National Systemic Amyloidosis RegistryNCT07689331 · Not reported · Semmelweis University · starts Mar 8, 2026
- Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired…NCT07654855 · Not reported · AstraZeneca · starts Sep 1, 2026
- Prevalence of Cardiac Thrombi in Cardiac AmyloidosisNCT07648303 · Not applicable · Centre Hospitalier Universitaire Dijon · starts Sep 7, 2026
- Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament BiopsyNCT07644325 · Not applicable · Clinique Saint Jean, France · starts May 27, 2026
- Elevated Rate Pacing of Cardiac AmyloidosisNCT07583823 · Not applicable · University of Minnesota · starts Oct 10, 2025
- [64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid CardiomyopathyNCT07560306 · Phase 3 · Brigham and Women's Hospital · starts Jul 7, 2026
Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications
Approved 1
- TafamidisTransthyretin stabiliser
Phase 3 11
- DexamethasoneGlucocorticoid receptor agonist
- Bortezomib26S proteasome inhibitor
- CyclophosphamideDNA inhibitor
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Ixazomib26S proteasome inhibitor
- BirtamimabLight chain aggregates inhibitor
- Anselamimab
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- PatisiranTransthyretin mRNA RNAi inhibitor
Phase 2 9
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- IsatuximabLymphocyte differentiation antigen CD38 inhibitor
- Belantamab mafodotinTumor necrosis factor receptor superfamily member 17 binding agent
- BendamustineDNA inhibitor
- AmiodaroneHERG blocker
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- ElotuzumabSLAM family member 7 inhibitor
- Epigalocatechin gallate
Phase 1 or earlier 5
- VenetoclaxApoptosis regulator Bcl-2 inhibitor
- Melphalan flufenamideDNA cross-linking agent
- Linvoseltamab
- Etentamig
- SelinexorExportin-1 inhibitor
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA